PMID- 36484513
OWN - NLM
STAT- MEDLINE
DCOM- 20230117
LR  - 20230117
IS  - 1364-6893 (Electronic)
IS  - 0144-3615 (Linking)
VI  - 43
IP  - 1
DP  - 2023 Dec
TI  - Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis.
PG  - 2151883
LID - 10.1080/01443615.2022.2151883 [doi]
AB  - This study aimed to evaluate the efficacy and safety of olaparib for the 
      treatment of advanced ovarian cancer. All studies that assessed the efficacy and 
      safety of olaparib in advanced ovarian cancer were searched in PubMed, Embase, 
      and Web of Science from their inception to 20 September 2022. The analysis 
      included six studies and 2016 patients. Olaparib could significantly prolong the 
      progression-free survival (PFS) of patients compared to that of the control group 
      (HR = 0.49, 95% CI = 0.36 - 0.68). However, no statistically significant 
      differences were detected in overall survival (OS) and objective response rate 
      (ORR) between the olaparib and control groups. Olaparib treatment increased the 
      number of grade >/=3 adverse events (AEs) in patients with advanced ovarian cancer 
      compared with that in the control group. Olaparib significantly prolonged PFS in 
      patients with advanced ovarian cancer; however, no statistically significant 
      differences were detected in OS and ORR. In terms of safety, olaparib has 
      manageable adverse effects.
FAU - Yang, Yuanyuan
AU  - Yang Y
AD  - Department of Obstetrics and Gynecology, Tongji Hospital Affiliated to Tongji 
      University, Shanghai, China.
FAU - Yang, Xiaoyun
AU  - Yang X
AD  - Department of Obstetrics and Gynecology, Tongji Hospital Affiliated to Tongji 
      University, Shanghai, China.
FAU - Li, Huaifang
AU  - Li H
AD  - Department of Obstetrics and Gynecology, Tongji Hospital Affiliated to Tongji 
      University, Shanghai, China.
FAU - Tong, Xiaowen
AU  - Tong X
AD  - Department of Obstetrics and Gynecology, Tongji Hospital Affiliated to Tongji 
      University, Shanghai, China.
FAU - Zhu, Xinxian
AU  - Zhu X
AD  - Department of Obstetrics and Gynecology, Tongji Hospital Affiliated to Tongji 
      University, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20221209
PL  - England
TA  - J Obstet Gynaecol
JT  - Journal of obstetrics and gynaecology : the journal of the Institute of 
      Obstetrics and Gynaecology
JID - 8309140
RN  - 0 (Antineoplastic Agents)
RN  - WOH1JD9AR8 (olaparib)
RN  - 0 (Phthalazines)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Antineoplastic Agents/adverse effects
MH  - *Ovarian Neoplasms/drug therapy
MH  - Carcinoma, Ovarian Epithelial
MH  - Phthalazines/adverse effects
OTO - NOTNLM
OT  - Ovarian cancer
OT  - meta-analysis
OT  - objective response rate
OT  - olaparib
OT  - overall survival
OT  - progression-free survival
EDAT- 2022/12/10 06:00
MHDA- 2023/01/18 06:00
CRDT- 2022/12/09 08:12
PHST- 2022/12/10 06:00 [pubmed]
PHST- 2023/01/18 06:00 [medline]
PHST- 2022/12/09 08:12 [entrez]
AID - 10.1080/01443615.2022.2151883 [doi]
PST - ppublish
SO  - J Obstet Gynaecol. 2023 Dec;43(1):2151883. doi: 10.1080/01443615.2022.2151883. 
      Epub 2022 Dec 9.